Cargando…

干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342536/
https://www.ncbi.nlm.nih.gov/pubmed/30929394
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.03.015
_version_ 1783555515321679872
collection PubMed
description
format Online
Article
Text
id pubmed-7342536
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73425362020-07-16 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察 Zhonghua Xue Ye Xue Za Zhi 经验交流 Editorial office of Chinese Journal of Hematology 2019-03 /pmc/articles/PMC7342536/ /pubmed/30929394 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.03.015 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 经验交流
干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
title 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
title_full 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
title_fullStr 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
title_full_unstemmed 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
title_short 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
title_sort 干扰素联合白细胞介素2治疗异基因造血干细胞移植术后高危及微小残留病升高患者疗效及安全性观察
topic 经验交流
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342536/
https://www.ncbi.nlm.nih.gov/pubmed/30929394
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.03.015
work_keys_str_mv AT gànrǎosùliánhébáixìbāojièsù2zhìliáoyìjīyīnzàoxuègànxìbāoyízhíshùhòugāowēijíwēixiǎocánliúbìngshēnggāohuànzhěliáoxiàojíānquánxìngguānchá
AT gànrǎosùliánhébáixìbāojièsù2zhìliáoyìjīyīnzàoxuègànxìbāoyízhíshùhòugāowēijíwēixiǎocánliúbìngshēnggāohuànzhěliáoxiàojíānquánxìngguānchá
AT gànrǎosùliánhébáixìbāojièsù2zhìliáoyìjīyīnzàoxuègànxìbāoyízhíshùhòugāowēijíwēixiǎocánliúbìngshēnggāohuànzhěliáoxiàojíānquánxìngguānchá
AT gànrǎosùliánhébáixìbāojièsù2zhìliáoyìjīyīnzàoxuègànxìbāoyízhíshùhòugāowēijíwēixiǎocánliúbìngshēnggāohuànzhěliáoxiàojíānquánxìngguānchá
AT gànrǎosùliánhébáixìbāojièsù2zhìliáoyìjīyīnzàoxuègànxìbāoyízhíshùhòugāowēijíwēixiǎocánliúbìngshēnggāohuànzhěliáoxiàojíānquánxìngguānchá